<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989414</url>
  </required_header>
  <id_info>
    <org_study_id>CC-92480-MM-002</org_study_id>
    <secondary_id>U1111-1233-5619</secondary_id>
    <secondary_id>2018-004767-31</secondary_id>
    <nct_id>NCT03989414</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)</brief_title>
  <official_title>A Phase 1/2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose&#xD;
      (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy&#xD;
      of CC-92480 in combination with standard treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting Toxicities (DLT)</measure>
    <time_frame>UP to approximately 2 years from enrollment</time_frame>
    <description>Number of participants with DLTs in the first cycle of the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From first subject first visit until 28 days after the last subject discontinues study treatment.</time_frame>
    <description>Type, frequency, seriousness and severity of adverse events (AEs), and relationship of AEs to study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>UP to approximately 3 years from enrollment</time_frame>
    <description>Defined as the proportion of subjects who achieve partial response (PR)or better according to the International Myeloma Working Group (IMWG) Uniform Response Criteria .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-response (TTR)</measure>
    <time_frame>UP to approximately 3 years from enrollment</time_frame>
    <description>Time from first dose to the first documentation of response (PR or greater)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to approximately 3 years from enrollment</time_frame>
    <description>Time from the first documentation of response (PR or greater) to the first documentation of progressive disease (PD) or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) rate</measure>
    <time_frame>Up to approximately 3 years from enrollment</time_frame>
    <description>Percentage of subjects who achieved CR or better according to IMWG Uniform Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very good partial response (VGPR) rate</measure>
    <time_frame>Up to approximately 3 years from enrollment</time_frame>
    <description>Percentage of subjects who achieved VGPR or better according to IMWG Uniform Response Criteria</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">408</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort A: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at specified cohort A dose administered over a 21-day cycle&#xD;
Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle&#xD;
Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (&gt; 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle in the first 8 cycles and on days 1, 2, 8 and 9 after Cycle 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: CC-92480 with carfilzomib and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at specified cohort C dose administered over a 28-day cycle&#xD;
Intravenous (IV) carfilzomib 20 mg/m2 then 56 mg/m2 administered over a 28-day cycle&#xD;
Oral/IV dexamethasone 40 mg/day (20 mg/day for subjects &gt; 75 years old) administered over a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort H: CC-92480 with elotuzumab and dexamathasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at specified cohort H dose administered over a 28-day cycle&#xD;
Intravenous ELO 10 mg/kg then 20 mg/kg administered over a 28-day cycle&#xD;
Oral (28 mg) and IV (8 mg) dexamethasone for total 36 mg/day (oral [8 mg] and IV [8 mg] dexamethasone for total 16 mg/day for subjects &gt; 75 years old) on ELO dosing days, and oral dexamethasone 40 mg/day (20 mg/day for subjects &gt; 75 years old) on non-ELO dosing days, administered over a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort I: CC-92480 with isatuximab and dexamathasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at specified cohort I dose administered over a 28-day cycle&#xD;
Intravenous ISA 10 mg/kg administered over a 28-day cycle&#xD;
Oral/IV dexamethasone 40 mg weekly (20 mg weekly for subjects &gt; 75 years old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at RP2D administered over a 21-day cycle&#xD;
Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle&#xD;
Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (&gt; 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle in the first 8 cycles and on days 1, 2, 8 and 9 after Cycle 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F: CC-92480 with carfilzomib and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at RP2D administered over a 28-day cycle&#xD;
Intravenous (IV) carfilzomib 20 mg/m2 then 56 mg/m2 administered over a 28-day cycle&#xD;
Oral/IV dexamethasone 40 mg/day (20 mg/day for subjects &gt; 75 years old) administered over a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J: CC-92480 with elotuzumab and dexamathasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at RP2D administered over a 28-day cycle&#xD;
Intravenous ELO 10 mg/kg then 20 mg/kg administered over a 28-day cycle&#xD;
Oral (28 mg)/IV (8 mg) dexamethasone for total 36 mg/day (oral [8 mg]/IV [8 mg] dexamethasone for total 16 mg/day for subjects &gt; 75 years old) on ELO dosing days, and oral dexamethasone 40 mg/day (20 mg/day for subjects &gt; 75 years old) on non-ELO dosing days, administered over a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort K: CC-92480 with isatuximab and dexamathasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at RP2D administered over a 28-day cycle&#xD;
Intravenous ISA 10 mg/kg administered over a 28-day cycle&#xD;
Oral/IV dexamethasone 40 mg weekly (20 mg weekly for subjects &gt; 75 years old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at RP2D administered over a 21-day cycle&#xD;
Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle up to Cycle 6&#xD;
Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (&gt; 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle up to Cycle 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcohort B1: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at specified cohort dose administered over a 28-day cycle&#xD;
Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes&#xD;
Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcohort B2: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at specified cohort dose administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards&#xD;
Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes&#xD;
Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight, administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcohort B3: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at specified cohort B dose administered over a 28-day cycle&#xD;
Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes&#xD;
Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcohort E1: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at RP2D administered over a 28-day cycle&#xD;
Either IV DARA administered at a dose of 16 mg/kg or SC DARA administered at a dose of 1800 mg over 3 to 5 minutes&#xD;
Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcohort E2: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at RP2D administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards&#xD;
Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes&#xD;
Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight, administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcohort E3: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CC-92480 at RP2D administered over a 28-day cycle&#xD;
Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes&#xD;
Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-92480</intervention_name>
    <description>CC-92480</description>
    <arm_group_label>Cohort A: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort C: CC-92480 with carfilzomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort D: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort F: CC-92480 with carfilzomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort G: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort H: CC-92480 with elotuzumab and dexamathasone</arm_group_label>
    <arm_group_label>Cohort I: CC-92480 with isatuximab and dexamathasone</arm_group_label>
    <arm_group_label>Cohort J: CC-92480 with elotuzumab and dexamathasone</arm_group_label>
    <arm_group_label>Cohort K: CC-92480 with isatuximab and dexamathasone</arm_group_label>
    <arm_group_label>Subcohort B1: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort B2: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort B3: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort E1: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort E2: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort E3: CC-92480 with daratumumab and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib</description>
    <arm_group_label>Cohort A: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort D: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort G: CC-92480 with bortezomib and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone</description>
    <arm_group_label>Cohort A: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort C: CC-92480 with carfilzomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort D: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort F: CC-92480 with carfilzomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort G: CC-92480 with bortezomib and dexamethasone</arm_group_label>
    <arm_group_label>Cohort H: CC-92480 with elotuzumab and dexamathasone</arm_group_label>
    <arm_group_label>Cohort I: CC-92480 with isatuximab and dexamathasone</arm_group_label>
    <arm_group_label>Cohort J: CC-92480 with elotuzumab and dexamathasone</arm_group_label>
    <arm_group_label>Cohort K: CC-92480 with isatuximab and dexamathasone</arm_group_label>
    <arm_group_label>Subcohort B1: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort B2: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort B3: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort E1: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort E2: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort E3: CC-92480 with daratumumab and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab</description>
    <arm_group_label>Subcohort B1: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort B2: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort B3: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort E1: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort E2: CC-92480 with daratumumab and dexamethasone</arm_group_label>
    <arm_group_label>Subcohort E3: CC-92480 with daratumumab and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib</description>
    <arm_group_label>Cohort C: CC-92480 with carfilzomib and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elotuzumab</intervention_name>
    <description>Elotuzumab</description>
    <arm_group_label>Cohort H: CC-92480 with elotuzumab and dexamathasone</arm_group_label>
    <arm_group_label>Cohort J: CC-92480 with elotuzumab and dexamathasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab</intervention_name>
    <description>Isatuximab</description>
    <arm_group_label>Cohort I: CC-92480 with isatuximab and dexamathasone</arm_group_label>
    <arm_group_label>Cohort K: CC-92480 with isatuximab and dexamathasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib</description>
    <arm_group_label>Cohort F: CC-92480 with carfilzomib and dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Key Inclusion criteria&#xD;
&#xD;
          -  Subject is ≥ to 18 years of age the time of signing the informed consent form (ICF).&#xD;
&#xD;
          -  Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of&#xD;
             0, 1 or 2.&#xD;
&#xD;
        For subjects in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also&#xD;
        apply:&#xD;
&#xD;
          -  Subject has documented diagnosis of MM and measurable disease, defined as: M-protein&#xD;
             quantities ≥ 0.5 g/dL by serum protein electrophoresis (sPEP) or ≥ 200 mg/24-hour&#xD;
             urine collection by urine protein electrophoresis (uPEP) and/or Serum free light chain&#xD;
             (FLC) levels &gt; 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda&#xD;
             (κ/λ) ratio in subjects without measurable disease in the serum or urine&#xD;
&#xD;
          -  Subject has received 2 to 4 (for Cohorts A, B, C, H, and I) or 1 to 3 (Cohorts D, E,&#xD;
             and F) or ≥ 2 (Cohorts J and K) prior anti-myeloma regimens.&#xD;
&#xD;
          -  Subject has received prior treatment with a lenalidomide-containing regimen for at&#xD;
             least 2 consecutive cycles.&#xD;
&#xD;
          -  Subject achieved a response (minimal response [MR] or better) to at least 1 prior&#xD;
             treatment regimen.&#xD;
&#xD;
          -  Subject must have documented disease progression during or after their last&#xD;
             anti-myeloma regimen.&#xD;
&#xD;
        For Cohorts J and K:&#xD;
&#xD;
          -  Subject has also received prior treatment with a proteasome inhibitor (bortezomib,&#xD;
             carfilzomib, or ixazomib) given alone or in combination for at least 2 consecutive&#xD;
             cycles AND&#xD;
&#xD;
          -  Subject has failed therapy with lenalidomide and a proteasome inhibitor, given alone&#xD;
             or in combination, defined as progression on or within 60 days of treatment, or&#xD;
             disease progression within 6 months after achieving at least a partial response.&#xD;
&#xD;
        Subject is refractory (progressed on or within 60 days of treatment) to their last&#xD;
        treatment.&#xD;
&#xD;
          -  Cohort F: Prior therapy with a proteasome inhibitor (PI), excluding carfilzomib, is&#xD;
             allowed as long as the subject had at least a PR to prior PI therapy, was not removed&#xD;
             from PI therapy due to toxicity, and will have at least a 6-month PI treatment-free&#xD;
             interval from last dose received until first study treatment (Subjects may receive&#xD;
             maintenance therapy with drugs that are not in PI class during this 6-month treatment&#xD;
             free interval).&#xD;
&#xD;
          -  For subjects in Cohort G, the following inclusions will also apply:&#xD;
&#xD;
        Considered by the investigator to be eligible for high-dose chemotherapy and autologous&#xD;
        stem cell transplantation (ASCT) according to the institution's criteria based on age,&#xD;
        medical history, cardiac and pulmonary status, overall health and condition, co-morbid&#xD;
        condition(s), physical examination, and laboratory.&#xD;
&#xD;
        Subject must have documented diagnosis with previously untreated symptomatic MM AND have&#xD;
        measurable disease, as assessed by central laboratory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Key Exclusion criteria&#xD;
&#xD;
          -  Subject has any of the following laboratory abnormalities:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &lt; 1,000/µL (for Phase 1 without growth factor&#xD;
                  support for ≥ 7 days [≥ 14 days for pegfilgrastim])&#xD;
&#xD;
               2. Platelet count: &lt; 75,000/µL (it is not permissible to transfuse a subject to&#xD;
                  reach this level)&#xD;
&#xD;
               3. Hemoglobin &lt; 8 g/dL (&lt; 4.9 mmol/L)&#xD;
&#xD;
               4. Creatinine clearance (CrCl) &lt; 45 mL/min (&lt; 30 mL/min for Cohort G)&#xD;
&#xD;
               5. Corrected serum calcium &gt; 13.5 mg/dL (&gt; 3.4 mmol/L)&#xD;
&#xD;
               6. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2.5 x&#xD;
                  ULN&#xD;
&#xD;
               7. Serum total bilirubin &gt; 1.5 x ULN or &gt; 3.0 mg/dL for subjects with documented&#xD;
                  Gilbert's syndrome&#xD;
&#xD;
               8. Prothrombin time (PT)/international normalized ratio (INR) 1.5 x ULN or partial&#xD;
                  thromboplastin time (PTT) 1.5 x ULN, (for subjects not receiving therapeutic&#xD;
                  anticoagulation).&#xD;
&#xD;
          -  Subject has peripheral neuropathy ≥ Grade 2&#xD;
&#xD;
          -  Subject with gastrointestinal disease that may significantly alter the absorption of&#xD;
             CC-92480.&#xD;
&#xD;
          -  Subject has prior history of malignancies, other than MM, unless the subject has been&#xD;
             free of the disease for ≥ 5 years with the exception of the following non-invasive&#xD;
             malignancies: Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin,&#xD;
             Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental&#xD;
             histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes,&#xD;
             metastasis] clinical staging system) or prostate cancer that is curative.&#xD;
&#xD;
          -  Subject has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome&#xD;
             (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)&#xD;
             or clinically significant amyloidosis.&#xD;
&#xD;
          -  Subject with known central nervous system (CNS) involvement with myeloma.&#xD;
&#xD;
          -  Subject has received immunosuppressive medication within the last 14 days of&#xD;
             initiating study treatment. The following are exceptions to this criterion:&#xD;
&#xD;
        Intranasal, inhaled, topical or local corticosteroid injections (eg, intra-articular&#xD;
        injection).&#xD;
&#xD;
          -  Systemic corticosteroids at doses that do not exceed 10 mg/day of prednisone or the&#xD;
             equivalent.&#xD;
&#xD;
          -  Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT]&#xD;
             scan premedication).&#xD;
&#xD;
          -  Subject has impaired cardiac function or clinically significant cardiac disease,&#xD;
             including any of the following:&#xD;
&#xD;
               1. Left ventricular ejection fraction (LVEF) &lt; 45% as determined by echocardiogram&#xD;
                  (ECHO) or multigated acquisition (MUGA) scan at Screening.&#xD;
&#xD;
                  Complete left bundle branch, bifascicular block or other clinically significant&#xD;
                  abnormal electrocardiogram (ECG) finding at Screening&#xD;
&#xD;
               2. A prolongation of QT interval on Screening ECG as defined by repeated&#xD;
                  demonstration of a QTc interval &gt; 470 milliseconds (msec) using Fridericia's QT&#xD;
                  correction formula; a history of or current risk factors for torsades de pointes&#xD;
                  (eg, heart failure, hypokalemia, or a family history of Long QT Syndrome); and&#xD;
                  concurrent administration of medications that prolong the QT/QTc interval&#xD;
                  Congestive heart failure (New York Heart Association Class III or IV).&#xD;
&#xD;
               3. Myocardial infarction within 12 months prior to starting study treatment.&#xD;
                  Unstable or poorly controlled angina pectoris, including the Prinzmetal variant&#xD;
                  of angina pectoris&#xD;
&#xD;
               4. History of severe coronary artery disease, severe uncontrolled ventricular&#xD;
                  arrhythmias, sick sinus syndrome, pericardial disease or electrocardiographic&#xD;
                  evidence of acute ischemia or Grade 3 conduction system abnormalities unless&#xD;
                  subject has a pacemaker&#xD;
&#xD;
               5. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to&#xD;
                  enrollment.&#xD;
&#xD;
               6. Concurrent administration of strong CYP3A modulators; concurrent administration&#xD;
                  of proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole,&#xD;
                  pantoprazole) ≤ 2 weeks prior to starting CC-92480.&#xD;
&#xD;
          -  Subject is a female who is pregnant, nursing or breastfeeding, or who intends to&#xD;
             become pregnant during the participation in the study.&#xD;
&#xD;
        Subject is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B,&#xD;
        or active hepatitis A or C.&#xD;
&#xD;
          -  Subject has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide,&#xD;
             pomalidomide, BTZ (for Cohorts A, D and G), DARA (for Cohorts B and E), CFZ (for&#xD;
             Cohorts C and F), ELO (for Cohorts H and J), ISA (for Cohorts I and K), or&#xD;
             dexamethasone.&#xD;
&#xD;
          -  Subject has known or suspected hypersensitivity to the excipients contained in the&#xD;
             formulation of CC-92480, BTZ (for Cohorts A, D and G), DARA (for Cohorts B and E), CFZ&#xD;
             (for Cohorts C and F), ELO (for Cohorts H and J), ISA (for Cohorts I and K), or&#xD;
             dexamethasone.&#xD;
&#xD;
          -  Contraindications to the standard treatment regimens, per local prescribing&#xD;
             information.&#xD;
&#xD;
          -  Subject is unable or unwilling to undergo protocol required thromboembolism&#xD;
             prophylaxis.&#xD;
&#xD;
        For subjects in Cohorts A, B, C, D, E, F, H, I, J, and K, the following exclusions will&#xD;
        also apply:&#xD;
&#xD;
          -  Subject received any of the following within the last 14 days of initiating study&#xD;
             treatment:&#xD;
&#xD;
               1. Plasmapheresis&#xD;
&#xD;
               2. Major surgery (as defined by the Investigator)&#xD;
&#xD;
               3. Radiation therapy other than local therapy for myeloma associated bone lesions&#xD;
&#xD;
               4. Use of any systemic anti-myeloma drug therapy&#xD;
&#xD;
               5. Cohorts A and D: Subjects who had progression during treatment or within 60 days&#xD;
                  of the last dose of BTZ or discontinued BTZ due to toxicity.&#xD;
&#xD;
               6. Cohorts B and I: Subjects who had progression during treatment or within 60 days&#xD;
                  of the last dose of DARA/ISA or discontinued DARA/ISA due to toxicity.&#xD;
&#xD;
               7. Cohort C: Subjects who had progression during treatment or within 60 days of the&#xD;
                  last dose of CFZ or discontinued CFZ due to toxicity.&#xD;
&#xD;
               8. Cohorts D, E, F, J, and K: Previous treatment with pomalidomide (POM).&#xD;
&#xD;
               9. Cohorts E and K: Previous treatment with DARA or ISA.&#xD;
&#xD;
              10. Cohort F: Previous treatment with CFZ.&#xD;
&#xD;
              11. Subject used any investigational agents within 28 days or 5 half-lives (whichever&#xD;
                  is longer) of initiating study treatment.&#xD;
&#xD;
              12. Subject has received previous allogeneic stem cell transplantation or received&#xD;
                  autologous stem cell transplantation within 12 weeks prior to starting study&#xD;
                  treatment.&#xD;
&#xD;
              13. Cohorts B, E, I, and K: Subject has known chronic obstructive pulmonary disease&#xD;
                  (COPD) with a forced expiratory volume in 1 second (FEV1) 50% of predicted&#xD;
                  normal. Note that forced expiratory testing (FEV1) is required for subjects&#xD;
                  suspected of having COPD and subjects must be excluded if FEV1 is &lt; 50% of&#xD;
                  predicted normal.&#xD;
&#xD;
              14. Cohorts B, E, I, and K: Subject has known moderate or severe persistent asthma,&#xD;
                  or currently has uncontrolled asthma of any classification.&#xD;
&#xD;
              15. Cohorts C and F: Subject has mild hepatic impairment defined as elevated&#xD;
                  bilirubin 1.0 but &lt; 1.5 x ULN or normal bilirubin with any elevation of AST.&#xD;
&#xD;
              16. Cohort H: Subjects who had progression during treatment or within 60 days of the&#xD;
                  last dose of ELO or discontinued ELO due to toxicity&#xD;
&#xD;
              17. Cohort J: Previous treatment with ELO&#xD;
&#xD;
                  For subjects in Cohort G, the following exclusion criteria will also apply:&#xD;
&#xD;
          -  Previous treatment with anti-myeloma therapy (does not include radiotherapy,&#xD;
             bisphosphonates, or a single short course of steroid [ie, less than or equal to the&#xD;
             equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid&#xD;
             treatment must not have been given within 14 days of initiating study treatment]).&#xD;
&#xD;
        For subjects in all cohorts:&#xD;
&#xD;
          -  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 14 days&#xD;
             for mild or asymptomatic infections or within 28 days for severe/critical illness&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Acute symptoms must have resolved and there must be no sequelae that would place the&#xD;
             subject at a higher risk of clinically significant complications from receiving study&#xD;
             treatment, based on the Investigator's assessment in consultation with the Sponsor&#xD;
             Medical Monitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Ghiddi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@bms.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Mass General Brigham Cancer Care, Inc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta - Faculty of Medicine and Dentistry</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charles University General Hospital</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez CHRU Lille</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette Hematologie</name>
      <address>
        <city>Marseille cedex</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu CHU Nantes</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Bretonneau</name>
      <address>
        <city>Tours cedex</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin Charité - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universitaet Muenchen</name>
      <address>
        <city>Munchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaets-klinikum Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alexandra General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>115 28</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili P.O. di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Citta della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopsital Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitario de Salamanca - Hospital Clinico</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universtario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed or Refractory Multiple Myeloma</keyword>
  <keyword>Newly Diagnosed Multiple Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>CC-92480</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Elotuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:&#xD;
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

